Lung Cancer Tumor Marker Tests: What They Are and Why They Matter

Lung cancer tumor marker testing plays a supportive role in clinical management, particularly for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). While imaging and histopathologic confirmation remain the diagnostic gold standards, serum tumor markers—including carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP)—provide valuable adjunctive information.

CYFRA 21-1 is highly sensitive for squamous cell carcinoma and adenocarcinoma of the lung. Elevated levels correlate with tumor burden and are useful for monitoring treatment response and detecting early recurrence. CEA, though less specific, often rises in adenocarcinoma and may aid in longitudinal surveillance, especially when baseline values are established prior to therapy.

NSE and ProGRP are neuroendocrine markers with heightened utility in SCLC. NSE demonstrates moderate sensitivity but limited specificity due to elevation in renal impairment or hemolysis; ProGRP offers superior specificity and stability, making it the preferred biomarker for SCLC diagnosis and follow-up. Serial measurements of these markers—particularly when combined—improve predictive value over single-timepoint assessment.

It is critical to emphasize that no tumor marker is diagnostic in isolation. False positives occur with benign pulmonary conditions (e.g., pneumonia, COPD, interstitial lung disease), chronic kidney disease, or smoking-related inflammation. Conversely, some patients with histologically confirmed lung cancer exhibit normal marker levels. Therefore, tumor markers must be interpreted within the full clinical context—including radiologic findings, histology, molecular profiling, and patient history—and never used as standalone screening tools.